Dasatinib-induced pulmonary arterial hypertension – A rare late complication
| العنوان: | Dasatinib-induced pulmonary arterial hypertension – A rare late complication |
|---|---|
| المؤلفون: | Vidhya Dhar, Amina Saqib, Uroosa Ibrahim, Marcel Odaimi |
| المصدر: | Journal of Oncology Pharmacy Practice. 25:727-730 |
| بيانات النشر: | SAGE Publications, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.drug_class, Hypertension, Pulmonary, Dasatinib, Antineoplastic Agents, Chronic phase chronic myelogenous leukemia, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Humans, Medicine, Pharmacology (medical), Protein Kinase Inhibitors, Second line treatment, business.industry, Late complication, ABL Tyrosine Kinase, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Cancer research, Female, business, 030215 immunology, Proto-oncogene tyrosine-protein kinase Src, medicine.drug |
| الوصف: | Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. Pulmonary arterial hypertension is defined by an increase in mean pulmonary arterial pressure >25 mmHg at rest. Dasatinib-induced pulmonary hypertension has been reported in less than 1% of patients on chronic dasatinib treatment for chronic myelogenous leukemia. The pulmonary arterial hypertension from dasatinib may be categorized as either group 1 (drug-induced) or group 5 based on various mechanisms that may be involved including the pathogenesis of the disease process of chronic myelogenous leukemia. There have been reports of dasatinib-induced pulmonary arterial hypertension being reversible. We report a case of pulmonary arterial hypertension in a 46-year-old female patient with chronic phase chronic myelogenous leukemia on dasatinib treatment for over 10 years. She had significant improvement in symptoms after discontinuation of dasatinib and initiation of vasodilators. Several clinical questions arise once patients experience significant adverse effects as discussed in our case. |
| تدمد: | 1477-092X 1078-1552 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6c80e621a2ccbbee79b7d19bf7233bd https://doi.org/10.1177/1078155217753740 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....c6c80e621a2ccbbee79b7d19bf7233bd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477092X 10781552 |
|---|